Pharma News - Alios BioPharma To Be Acquired By Johnson & Johnson

Back to NAM Blog

Pharma News - Alios BioPharma To Be Acquired By Johnson & Johnson

In pharma news, on September 30, Johnson & Johnson announced the company would be purchasing Alios BioPharma, Inc. for approximately $1.75 billion in cash. Alios BioPharma is a privately held clinical stage pharmaceutical company whose focus is on the development of effective therapies for viral diseases. According to the news release, in acquiring the pharmaceutical company, Johnson & Johnson will acquire a compound designed for oral administration currently being studied for treatment of RSV, or respiratory syncytial virus, in infants. This compound is known as AL-8176. Global Head of R & D at Janssen Pharmaceutical Companies of Johnson & Johnson, William N. Hait, M.D., Ph.D., said that the company is excited about the acquisition which will allow Johnson & Johnson to explore treatment options for RSV and other viral infections. The purchase should be complete during the fourth quarter of this year, and is subject to conditions including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. At Markem-Imaje, we know Johnson & Johnson is excited about this acquisition and the possibility of treating RSV, a major disease in children under the age of five that currently has no available preventive therapy. As a trusted supplier of industrial coding and marking solutions in the pharmaceutical industry, we understand how vital quality, indelible coding is in not only the pharma industry, but every industry. We provide a wide array of marking solutions, and proudly supply our inkjet, thermal transfer, and laser printing solutions to manufacturers around the world.

January 10, 2014
Markem-Imaje Announces Acquisition of CSAT

Markem-Imaje Announces Acquisition of CSAT
Back to top